BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henson LJ, Afsar S, Davenport L, Purvis A, Poole EM, Truffinet P. Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. Reprod Toxicol 2020;95:45-50. [PMID: 32407881 DOI: 10.1016/j.reprotox.2020.04.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Andersen JB, Wandall-holm MF, Magyari M. Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population. Multiple Sclerosis and Related Disorders 2022;59:103529. [DOI: 10.1016/j.msard.2022.103529] [Reference Citation Analysis]
2 Varytė G, Arlauskienė A, Ramašauskaitė D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol 2021;33:378-83. [PMID: 34310364 DOI: 10.1097/GCO.0000000000000731] [Reference Citation Analysis]
3 Al Jumah M, Al Malik Y, AlKhawajah NM, Saeedi J, AlThubaiti I, Bohlega S, Bunyan RF, Cupler EJ, ElBoghdady A, Hassan A, Ali EN, Clerico M. Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus. Mult Scler Int 2021;2021:6667006. [PMID: 33628508 DOI: 10.1155/2021/6667006] [Reference Citation Analysis]
4 Häfeli C, Förger F. [Current aspects of antirheumatic therapy in pregnancy planning, during pregnancy and breastfeeding]. Z Rheumatol 2021;80:716-25. [PMID: 34581874 DOI: 10.1007/s00393-021-01095-z] [Reference Citation Analysis]